Alpine Global Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alpine Global Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,504	Closed	-$206K	–	194
2024 Q2	$206K	Buy	+2,504	New	+$208K	0.04%	305
2023 Q3	–	Sell	-9,300	Closed	-$806K	–	167
2023 Q2	$806K	Buy	+9,300	New	+$875K	0.22%	58

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Alpine Global Management's BMRN Position: Q3 2024 in Review

Alpine Global Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,504 shares — an estimated $206K sold.

Alpine Global Management first reported a position in BMRN in Q2 2023 and held it in 2 quarters. The position peaked at $806K in Q2 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Alpine Global Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Alpine Global Management sold 2,504 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $206K.
Alpine Global Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 2 quarters.
Alpine Global Management's BioMarin Pharmaceuticals position peaked at $806K in Q2 2023.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.